^
    Back
    Association details:
    Biomarker:PTEN deletion + BRCA1 mutation
    Cancer:Breast Cancer
    Drug:Lynparza (olaparib) (PARP inhibitor) +
    Imfinzi (durvalumab) (PD-L1 inhibitor) +
    Truqap (capivasertib) (AKT inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO 2021
    Title:

    515MO - A phase I trial of durvalumab (Durv) in combination with olaparib (Ola) and capivasertib (Cap) in patients (pts) with advanced or metastatic cancers (Ca) (MEDIPAC)

    Published date:
    09/13/2021
    Excerpt:
    We hypothesized that triplet combination of immunotherapy with PARP and PI3K-AKT pathway inhibition is tolerable and may demonstrate activity in pts with relevant pathway defects. We investigated the safety and tolerability, pharmacodynamics (PD) and antitumor activity of Durv+Ola, with escalating doses of Cap. 1 pt with PIK3CA E545K mutant breast Ca had stable disease (SD) for 5 months, and 1 pt with PTEN loss and BRCA1 mutant breast Ca had SD of 6 months despite prior progression on PARP inhibitor. Triplet Cap+Ola+Durv is tolerable with evidence of PD and antitumor activity.
    Trial ID:
    MEDIPAC